Skip to main navigation Skip to search Skip to main content

Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey

  • Clara Natoli
  • , Davide Brocco
  • , Isabella Sperduti
  • , Antonio Nuzzo
  • , Nicola Tinari
  • , Michele De Tursi
  • , Antonino Grassadonia
  • , Lorenzo Mazzilli
  • , Stefano Iacobelli
  • , Teresa Gamucci
  • , Patrizia Vici

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: Breast cancer follow-up procedures after primary treatment are still a controversial issue. Aim of this study was to investigate, through a web-based survey, surveillance methodologies selected by Italian oncologists in everyday clinical practice. Methods: Referents of Italian medical oncology units were invited to participate to the study via e-mail through the SurveyMonkey website. Participants were asked how, in their institution, exams of disease staging and follow-up are planned in asymptomatic women and if surveillance continues beyond the 5th year. Results: Between February and May 2013, 125 out of 233 (53.6%) invited referents of Italian medical oncology units agreed to participate in the survey. Ninety-seven (77.6%) referents state that modalities of breast cancer follow-up are planned according to the risk of disease progression at diagnosis and only 12 (9.6%) oncology units apply the minimal follow-up procedures according to international guidelines. Minimal follow-up is never applied in high risk asymptomatic women. Ninety-eight (78.4%) oncology units continue follow-up in all patients beyond 5 years. Conclusions: Our survey shows that 90.4% of participating Italian oncology units declare they do not apply the minimal breast cancer follow-up procedures after primary treatment in asymptomatic women, as suggested by national and international guidelines. Interestingly, about 80.0% of interviewed referents performs the so called "tailored follow-up", high intensity for high risk, low intensity for low risk patients. There is an urgent need of randomized clinical trials able to determine the effectiveness of risk-based follow-up modalities, their ideal frequency and persistence in time.

Original languageEnglish
Article numbere94063
JournalPLoS ONE
Volume9
Issue number4
DOIs
Publication statusPublished - 8 Apr 2014
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey'. Together they form a unique fingerprint.

Cite this